Cytomegalovirus (CMV) Forecasts 2027 Opportunity Analysis by Atara Bio, Biotest AG, Helocyte, Merck & Co., Novartis, Shire, ViraCyte

Cytomegalovirus (CMV) is a ? human herpesvirus (HHV-5) of the herpesviridae family. Exposure to the virus can result in lytic infection, producing symptoms that range from those of a common cold to more serious morbidities, including hepatitis and pneumonitis. CMV also has the capacity to establish life-long latent infections, incorporating genomic DNA into host cells without detectable viral gene expression. CMV is a globally ubiquitous pathogen that affects 1/3 of children by the age of 5 and over half of adults by the age of 40. Although largely asymptomatic in immunocompetent adults, CMV infection is a clinically significant disease in patients with compromised immune systems or those receiving immunosuppressive therapy. Particularly vulnerable patients include solid organ transplant (SOT), bone marrow transplant (BMT), hematopoietic stem cell transplant (HSCT), and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) patients, as well as newborns that acquire the infection by transmission from the mother through the placenta.

Get Sample Copy of This Report at @ https://www.orbisresearch.com/contacts/request-sample/2363476

Currently available therapies for CMV can be divided into two general classes: antiviral drugs for treatment of clinically significant CMV infections and antiviral drugs for CMV prophylaxis. The majority of antivirals are administered in a clinical setting as both therapy and prophylaxis, with variations in dosing parameters depending on the treated patient population. However, major shifts are expected to occur in the CMV market during the forecast period with the projected launch of first-in-class products for CMV therapy and prophylaxis, including cellular immunotherapy and a CMV vaccine.

Key Top Leading Companies Mentioned:
Atara Bio
Biotest AG
Helocyte
Merck & Co.
Novartis
Shire
ViraCyte

Key Questions Answered

- How will the CMV therapeutic market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2017-2027?
- What are the most promising late-stage pipeline drugs for CMV?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the remaining unmet needs in CMV treatment management?
- What drivers and barriers will affect CMV therapeutics sales in the 7MM over the forecast period?

Scope

- Overview of CMV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline CMV market revenue from 2017-2027. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment and prophylactic options, unmet needs and opportunities, and the drivers and barriers affecting CMV therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global CMV therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Else place an Inquire before Purchase@ https://www.orbisresearch.com/contacts/enquiry-before-buying/2363476

Reasons to buy

The report will enable you to - 
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CMV therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CMV therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships. 

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com

This release was published on openPR.